Atara Biotherapeutics (ATRA) Assets (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Assets came in at $20.0 million in Q1 2026, down 67.77% YoY from $62.0 million in Q1 2025, and down 1.18% on a QoQ basis from $20.2 million in Q4 2025.
Atara Biotherapeutics (ATRA) Assets (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Assets data on file, last reported at $20.0 million in Q1 2026.
- Quarterly Assets fell 67.77% year-over-year to $20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.0 million (down 67.77% YoY) and the FY2025 annual result came in at $20.2 million, down 81.45% from the prior year.
- Assets retreated to $20.0 million in Q1 2026, from $20.2 million in the prior quarter.
- In the past five years, Assets ranged from a high of $436.1 million in Q2 2022 to a low of $20.0 million in Q1 2026.
- A 5-year average of $187.3 million and a median of $165.3 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets slipped 4.53% — and 2025, when it sank 81.45%.
- Tracing ATRA's Assets over 5 years: stood at $376.4 million in 2022, then slumped by 56.03% to $165.5 million in 2023, then slumped by 34.08% to $109.1 million in 2024, then slumped by 81.45% to $20.2 million in 2025, then dropped by 1.18% to $20.0 million in 2026.
- The last three Assets figures came in at $20.0 million (Q1 2026), $20.2 million (Q4 2025), and $30.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.65 Bn | 131.79 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 86.08 Bn | 78.09 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 63.25 Bn | 58.11 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.26 Bn | 27.95 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.96 Bn | 10.57 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.19 Bn | 26.35 Bn | - | 19.82 Bn |
| 10 | Atara Biotherapeutics | 146.12 Mn | 129.57 Mn | 439,000.00 | 21.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.02 Mn |
| Mar 31, 2026 | 20.00 Mn |
| Dec 31, 2025 | 20.24 Mn |
| Sep 30, 2025 | 30.17 Mn |
| Jun 30, 2025 | 36.90 Mn |
| Mar 31, 2025 | 62.04 Mn |
| Dec 31, 2024 | 109.10 Mn |
| Sep 30, 2024 | 142.71 Mn |
| Jun 30, 2024 | 117.28 Mn |
| Mar 31, 2024 | 165.27 Mn |
| Dec 31, 2023 | 165.50 Mn |
| Sep 30, 2023 | 188.79 Mn |
| Jun 30, 2023 | 246.44 Mn |
| Mar 31, 2023 | 302.08 Mn |
| Dec 31, 2022 | 376.42 Mn |
| Sep 30, 2022 | 368.32 Mn |
| Jun 30, 2022 | 436.12 Mn |
| Mar 31, 2022 | 397.28 Mn |
| Dec 31, 2021 | 468.13 Mn |
| Sep 30, 2021 | 449.92 Mn |